Genzyme/Schering AG To Initiate Campath Phase III Trial For MS
Firms agree with FDA on Phase III plan despite suspension of Phase II program following three cases of severe idiopathic thrombocytopenic purpura.
Firms agree with FDA on Phase III plan despite suspension of Phase II program following three cases of severe idiopathic thrombocytopenic purpura.